Preventive and therapeutic effects of mg132 by activating nrf2-are signaling pathway on oxidative stress-induced cardiovascular and renal injury

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Cui, Wenpeng ^a,b   Bai, Yang ^b,c   Luo, Ping ^a   Miao, Lining ^a   Cai, Lu ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c People's Hospital of Jilin Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMIC BURDEN; OXIDATIVE DAMAGE; RENAL DISEASE; RENAL INJURY; SIGNALING PATHWAYS; STRESS-INDUCED; THERAPEUTIC EFFECTS; THERAPEUTIC STRATEGY;

CHEMICAL ACTIVATION; DISEASE CONTROL; DISEASES; OXIDATIVE STRESS; TISSUE;

SIGNALING;

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN;

ANTIOXIDANT RESPONSIVE ELEMENT; AORTA DISEASE; CELL PROTECTION; DETOXIFICATION; DIABETES MELLITUS; GENE EXPRESSION; HEART INJURY; HUMAN; KIDNEY INJURY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECT; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANT RESPONSE ELEMENTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; LEUPEPTINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84875527422     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/306073     Document Type: Review

References (131)

1. Stop the global epidemic of chronic disease-new report, preventing chronic diseases: a vital investment estimates hundreds of billions of dollars at stake. Indian Journal of Medical Sciences 2005 59 10 463 465
2. Morabia A., Abel T., The WHO report "Preventing chronic diseases: a vital investment" and us. Sozial- und Praventivmedizin 2006 51 2 74 2-s2.0-33745238043 10.1007/s00038-005-0015-7 (Pubitemid 43923170)
3. Nissenson A. R., Pereira B. J. G., Collins A. J., Steinberg E. P., Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. American Journal of Kidney Diseases 2001 37 6 1177 1183 2-s2.0-0034995027 (Pubitemid 32525153)
4. Weir M. R., Recognizing the link between chronic kidney disease and cardiovascular disease. American Journal of Managed Care 2011 17 supplement 15 S396 S402
5. Schiffrin E. L., Lipman M. L., Mann J. F. E., Chronic kidney disease: effects on the cardiovascular system. Circulation 2007 116 1 85 97 2-s2.0-34347350171 10.1161/CIRCULATIONAHA.106.678342 (Pubitemid 47016250)
6. Cui W., Du B., Zhou W., Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis. Molecular Biology Reports 2012 39 8 8551 8558
7. Cui W. P., Du B., Jia Y., Is C677T polymorphism in methylenetetrahydrofolate reductase gene a risk factor for diabetic nephropathy or diabetes mellitus in a Chinese population? Archives of Medical Research 2012 43 1 42 50
8. Wareham N. J., Pfister R., Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk. Nature Reviews Cardiology 2010 7 7 367 368 2-s2.0-77954149685 10.1038/nrcardio.2010.84
9. Lea J. P., McClellan W. M., Melcher C., Gladstone E., Hostetter T., CKD risk factors reported by primary care physicians: do guidelines make a difference? American Journal of Kidney Diseases 2006 47 1 72 77 2-s2.0-29244475053 10.1053/j.ajkd.2005.09.027 (Pubitemid 41828268)
10. Tsuruya K., Hirakata H., Anemia as a risk factor for CKD and CVD. Nippon Rinsho 2008 66 9 1786 1793 2-s2.0-54049149844
11. Chu M., Wang A. Y., Chan I. H., Chui S. H., Lam C. W., Serum small-dense LDL abnormalities in chronic renal disease patients. British Journal of Biomedical Science 2012 69 3 99 102
12. Ansar S., Koska J., Reaven P. D., Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovascular Diabetology 2011 10, article 61 2-s2.0-79960019675 10.1186/1475-2840-10-61
13. Ramos L. F., Shintani A., Ikizler T. A., Himmelfarb J., Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. Journal of the American Society of Nephrology 2008 19 3 593 599 2-s2.0-40449129185 10.1681/ASN.2007030355 (Pubitemid 351355403)
14. Higdon J. V., Frei B., Obesity and oxidative stress: a direct link to CVD? Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 3 365 367 2-s2.0-0037339716 10.1161/01.ATV.0000063608.43095.E2 (Pubitemid 36337206)
15. Burton G. J., Jauniaux E., Oxidative stress. Best Practice & Research Clinical Obstetrics & Gynaecology 2011 25 3 287 299
16. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., Green M. S., Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. The Lancet 2000 356 9237 1213 1218 2-s2.0-0034619027
17. Wijnen M. H. W. A., Vader H. L., Van Den Wall Bake A. W. L., Roumen R. M. H., Can renal dysfunction after infra-renal aortic aneurysm repair be modified by multi-antioxidant supplementation? Journal of Cardiovascular Surgery 2002 43 4 483 488 2-s2.0-0036696651
18. Mann J. F. E., Lonn E. M., Yi Q., Gerstein H. C., Hoogwerf B. J., Pogue J., Bosch J., Dagenais G. R., Yusuf S., Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE Study. Kidney International 2004 65 4 1375 1380 2-s2.0-1642422335 10.1111/j.1523-1755.2004.00513.x (Pubitemid 38406976)
19. Muthusamy V. R., Kannan S., Sadhaasivam K., Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radical Biology & Medicine 2012 52 2 366 376
20. Krajka-Kuzniak V., Paluszczak J., Celewicz L., Barciszewski J., Baer-Dubowska W., Phloretamide, an apple phenolic compound, activates the Nrf2/ARE pathway in human hepatocytes. Food and Chemical Toxicology 2013 51 202 209
21. Duan W., Guo Y., Jiang H., Yu X., Li C., MG132 enhances neurite outgrowth in neurons overexpressing mutant TAR DNA-binding protein-43 via increase of HO-1. Brain Research 2011 1397 1 9 2-s2.0-79958262155 10.1016/j.brainres.2011. 05.006
22. Luo Z. F., Qi W., Feng B., Mu J., Zeng W., Guo Y. H., Pang Q., Ye Z. L., Liu L., Yuan F. H., Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sciences 2011 88 11-12 512 520 2-s2.0-79952455513 10.1016/j.lfs.2010.12.023
23. Dreger H., Westphal K., Weller A., Baumann G., Stangl V., Meiners S., Stangl K., Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovascular Research 2009 83 2 354 361 2-s2.0-67650229881 10.1093/cvr/cvp107
24. Sahni S. K., Rydkina E., Sahni A., The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells. Thrombosis Research 2008 122 6 820 825 2-s2.0-52049100130 10.1016/j.thromres.2008.01.011
25. Aiken C. T., Kaake R. M., Wang X., Huang L., Oxidative stress-mediated regulation of proteasome complexes. Molecular and Cellular Proteomics 2011 10 5 R110.006924 2-s2.0-79955757695 10.1074/mcp.R110.006924
26. D'Autréaux B., Toledano M. B., ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nature Reviews Molecular Cell Biology 2007 8 10 813 824 2-s2.0-34648813720 10.1038/nrm2256 (Pubitemid 47462134)
27. Dröge W., Free radicals in the physiological control of cell function. Physiological Reviews 2002 82 1 47 95 2-s2.0-0036086130 (Pubitemid 34654215)
28. Lyakhovich V. V., Vavilin V. A., Zenkov N. K., Menshchikova E. B., Active defense under oxidative stress. The antioxidant responsive element. Biochemistry 2006 71 9 962 974 2-s2.0-34547315612 10.1134/S0006297906090033
29. Mo C., Dai Y., Kang N., Cui L., He W., Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. The Journal of Biological Chemistry 2012 287 23 19242 19254
30. Williams V., Brichler S., Khan E., Large hepatitis delta antigen activates STAT-3 and NF-kappaB via oxidative stress. Journal of Viral Hepatitis 2012 19 10 744 753
31. Chiu W. C., Chen C. J., Lee T. S., Chen Z. J., Ke P. H., Chiang A. N., Oxidative stress enhances AP-1 and NF- B-mediated regulation of β 2-Glycoprotein I gene expression in hepatoma cells. Journal of Cellular Biochemistry 2010 111 4 988 998 2-s2.0-78049291850 10.1002/jcb.22787
32. Hool L. C., Corry B., Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxidants and Redox Signaling 2007 9 4 409 435 2-s2.0-33847232634 10.1089/ars.2006.1446
33. Pillon N. J., Croze M. L., Vella R. E., Soulere L., Lagarde M., Soulage C. O., The lipid peroxidation by-product 4-hydroxy-2-nonenal (4-HNE) induces insulin resistance in skeletal muscle through both carbonyl and oxidative stress. Endocrinology 2012 153 5 2099 2111
34. Kaya Y., Cebi A., Soylemez N., Demir H., Alp H. H., Bakan E., Correlations between oxidative DNA damage, oxidative stress and coenzyme Q10 in patients with coronary artery disease. International Journal of Medical Sciences 2012 9 8 621 626
35. Piomboni P., Stendardi A., Gambera L., Protein modification as oxidative stress marker in normal and pathological human seminal plasma. Redox Report 2012 17 5 227 232
36. Nguyen T., Sherratt P. J., Pickett C. B., Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annual Review of Pharmacology and Toxicology 2003 43 233 260 2-s2.0-0037763721 10.1146/annurev.pharmtox.43.100901.140229 (Pubitemid 37372641)
37. Alam J., Cook J. L., Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Current Pharmaceutical Design 2003 9 30 2499 2511 2-s2.0-0141885079 10.2174/1381612033453730 (Pubitemid 37236369)
38. Kong A. N. T., Owuor E., Yu R., Hebbar V., Chen C., Hu R., Mandlekar S., Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metabolism Reviews 2001 33 3-4 255 271 2-s2.0-0035212419 10.1081/DMR-120000652 (Pubitemid 33136265)
39. Hayes J. D., McMahon M., NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences 2009 34 4 176 188 2-s2.0-63549121490 10.1016/j.tibs.2008.12.008
40. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J. D., Yamamoto M., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and Development 1999 13 1 76 86 2-s2.0-0032953192 (Pubitemid 29045117)
41. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., Yamamoto M., Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes to Cells 2003 8 4 379 391 2-s2.0-12444257799 10.1046/j.1365-2443.2003.00640.x (Pubitemid 36504013)
42. Stewart D., Killeen E., Naquin R., Alam S., Alam J., Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. The Journal of Biological Chemistry 2003 278 4 2396 2402 2-s2.0-0037462651 10.1074/jbc.M209195200 (Pubitemid 36801313)
43. Dinkova-Kostova A. T., Holtzclaw W. D., Cole R. N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P., Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11908 11913 2-s2.0-0037015035 10.1073/pnas.172398899 (Pubitemid 34994497)
44. Wakabayashi N., Dinkova-Kostova A. T., Holtzclaw W. D., Kang M. I., Kobayashi A., Yamamoto M., Kensler T. W., Talalay P., Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proceedings of the National Academy of Sciences of the United States of America 2004 101 7 2040 2045 2-s2.0-1242296811 10.1073/pnas.0307301101 (Pubitemid 38229011)
45. Min K. J., Kim J. H., Jou I., Joe E. H., Adenosine induces hemeoxygenase-1 expression in microglia through the activation of phosphatidylinositol 3-kinase and nuclear factor E2-related factor 2. GLIA 2008 56 9 1028 1037 2-s2.0-51349110613 10.1002/glia.20676
46. Kalayarasan S., Prabhu P. N., Sriram N., Manikandan R., Arumugam M., Sudhandiran G., Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. European Journal of Pharmacology 2009 606 1-3 162 171 2-s2.0-61449134946 10.1016/j.ejphar.2008.12.055
47. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., Nabeshima Y. I., An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications 1997 236 2 313 322 2-s2.0-0031577292 10.1006/bbrc.1997.6943 (Pubitemid 27373291)
48. Gong P., Hu B., Cederbaum A. I., Diallyl sulfide induces heme oxygenase-1 through MAPK pathway. Archives of Biochemistry and Biophysics 2004 432 2 252 260 2-s2.0-7944220437 10.1016/j.abb.2004.09.024 (Pubitemid 39470021)
49. Huang H. C., Nguyen T., Pickett C. B., Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. The Journal of Biological Chemistry 2002 277 45 42769 42774 2-s2.0-0037044791 10.1074/jbc.M206911200 (Pubitemid 35285650)
50. Huang H. C., Nguyen T., Pickett C. B., Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proceedings of the National Academy of Sciences of the United States of America 2000 97 23 12475 12480 2-s2.0-0033731182 10.1073/pnas.220418997
51. Shen G., Jeong W. S., Hu R., Kong A. N. T., Regulation of Nrf2, NF- B, and AP-1 signaling pathways by chemopreventive agents. Antioxidants and Redox Signaling 2005 7 11-12 1648 1663 2-s2.0-28844501753 10.1089/ars.2005.7.1648 (Pubitemid 41767999)
52. Nixon R. A., Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. American Journal of Pathology 2004 164 3 757 761 2-s2.0-1242316279 (Pubitemid 38235457)
53. Vlachostergios P. J., Voutsadakis I. A., Papandreou C. N., The ubiquitin-proteasome system in glioma cell cycle control. Cell Division 2012 7, article 18
54. Sohns W., van Veen T. A. B., van der Heyden M. A. G., Regulatory roles of the ubiquitin-proteasome system in cardiomyocyte apoptosis. Current Molecular Medicine 2010 10 1 1 13 2-s2.0-77949447748 10.2174/156652410791065426
55. Bhat K. P., Greer S. F., Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochimica et Biophysica Acta 2011 1809 2 150 155 2-s2.0-79251596169 10.1016/j.bbagrm.2010.11.006
56. Imai F., Yoshizawa A., Fujimori-Tonou N., Kawakami K., Masai I., The ubiquitin proteasome system is required for cell proliferation of the lens epithelium and for differentiation of lens fiber cells in zebrafish. Development 2010 137 19 3257 3268 2-s2.0-77956594634 10.1242/dev.053124
57. Rezvani K., Teng Y., De Biasi M., The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors. Journal of Molecular Neuroscience 2010 40 1-2 177 184 2-s2.0-75049083231 10.1007/s12031-009-9272-x
58. Bahrudin U., Morikawa K., Takeuchi A., Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. Journal of Molecular Biology 2011 413 4 857 878
59. Villeneuve N. F., Lau A., Zhang D. D., Regulation of the Nrf2-keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxidants and Redox Signaling 2010 13 11 1699 1712 2-s2.0-77958115724 10.1089/ars.2010.3211
60. Adams J., The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews 2003 29 supplement 1 3 9 2-s2.0-0037852202 (Pubitemid 36626287)
61. Chen Z., Hagler J., Palombella V. J., Melandri F., Scherer D., Ballard D., Maniatis T., Signal-induced site-specific phosphorylation targets I B α to the ubiquitin-proteasome pathway. Genes and Development 1995 9 13 1586 1597 2-s2.0-0029146930
62. Tanaka K., Mizushima T., Saeki Y., The proteasome: molecular machinery and pathophysiological roles. Biological Chemistry 2012 393 4 217 234
63. Nickell S., Beck F., Scheres S. H. W., Korinek A., Förster F., Lasker K., Mihalache O., Sun N., Nagy I., Sali A., Plitzko J. M., Carazo J. M., Mann M., Baumeister W., Insights into the molecular architecture of the 26S proteasome. Proceedings of the National Academy of Sciences of the United States of America 2009 106 29 11943 11947 2-s2.0-67749095289 10.1073/pnas.0905081106
64. Goldberg A. L., Stein R., Adams J., New insights into proteasome function: from archaebacteria to drug development. Chemistry and Biology 1995 2 8 503 508 2-s2.0-0029347062 10.1016/1074-5521(95)90182-5
65. Lee D. H., Goldberg A. L., Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. The Journal of Biological Chemistry 1996 271 44 27280 27284 2-s2.0-0000870917 10.1074/jbc.271.44.27280 (Pubitemid 26367280)
66. Majetschak M., Patel M. B., Sorell L. T., Liotta C., Li S., Pham S. M., Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochemical and Biophysical Research Communications 2008 365 4 882 888 2-s2.0-36849041155 10.1016/j.bbrc.2007.11.092 (Pubitemid 350234876)
67. Yamamoto N., Sawada H., Izumi Y., Kume T., Katsuki H., Shimohama S., Akaike A., Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. The Journal of Biological Chemistry 2007 282 7 4364 4372 2-s2.0-33947517977 10.1074/jbc.M603712200 (Pubitemid 47101000)
68. Usami H., Kusano Y., Kumagai T., Osada S., Itoh K., Kobayashi A., Yamamoto M., Uchida K., Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors. The Journal of Biological Chemistry 2005 280 26 25267 25276 2-s2.0-21644467011 10.1074/jbc.M501014200 (Pubitemid 40934621)
69. Nguyen T., Sherratt P. J., Huang H. C., Yang C. S., Pickett C. B., Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26 S proteasome. The Journal of Biological Chemistry 2003 278 7 4536 4541 2-s2.0-0013282861 10.1074/jbc.M207293200 (Pubitemid 36800950)
70. Kraft D. C., Deocaris C. C., Wadhwa R., Rattan S. I. S., Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts. Annals of the New York Academy of Sciences 2006 1067 1 420 424 2-s2.0-33744477355 10.1196/annals.1354. 060 (Pubitemid 43806354)
71. Lorenz M., Wilck N., Meiners S., Ludwig A., Baumann G., Stangl K., Stangl V., Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sciences 2009 84 25-26 929 934 2-s2.0-67349205896 10.1016/j.lfs.2009.04.016
72. Du Z. X., Zhang H. Y., Meng X., Gao Y. Y., Zou R. L., Liu B. Q., Guan Y., Wang H. Q., Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1. Journal of Cellular Physiology 2009 218 3 631 637 2-s2.0-58149375078 10.1002/jcp.21634
73. Zanotto-Filho A., Braganhol E., Battastini A. M., Moreira J. C., Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Investigational New Drugs 2012 30 6 2252 2262
74. Park W. H., Kim S. H., MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncology Reports 2012 27 4 1284 1291
75. Balasubramanian S., Kanade S., Han B., Eckert R. L., A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level. The Journal of Biological Chemistry 2012 287 43 36179 36189
76. Radhakrishnan S. K., Lee C. S., Young P., Beskow A., Chan J. Y., Deshaies R. J., Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Molecular Cell 2010 38 1 17 28 2-s2.0-77950366349 10.1016/j.molcel.2010.02.029
77. Pickering A. M., Linder R. A., Zhang H., Forman H. J., Davies K. J., Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. The Journal of Biological Chemistry 2012 287 13 10021 10031
78. Fratta Pasini A., Albiero A., Stranieri C., Serum oxidative stress-induced repression of Nrf2 and GSH depletion: a mechanism potentially involved in endothelial dysfunction of young smokers. PLoS One 2012 7 1 e30291
79. Gebhard C., Stahli B. E., Shi Y., Poly(ADP-ribose) polymerase-1 protects from oxidative stress induced endothelial dysfunction. Biochemical and Biophysical Research Communications 2011 414 4 641 646
80. Andreassi M. G., Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutation Research 2003 543 1 67 86 2-s2.0-0037221513 10.1016/S1383-5742(02)00089-3 (Pubitemid 36050913)
81. Gray K., Bennett M., Role of DNA damage in atherosclerosis-bystander or participant? Biochemical Pharmacology 2011 82 7 693 700
82. Neuzil J., Rayner B. S., Lowe H. C., Witting P. K., Oxidative stress in myocardial ischaemia reperfusion injury: a renewed focus on a long-standing area of heart research. Redox Report 2005 10 4 187 197 2-s2.0-33646852199 10.1179/135100005X57391 (Pubitemid 44111135)
83. He X., Kan H., Cai L., Ma Q., Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. Journal of Molecular and Cellular Cardiology 2009 46 1 47 58 2-s2.0-57249104720 10.1016/j.yjmcc.2008.10. 007
84. Chen X. L., Dodd G., Thomas S., Zhang X., Wasserman M. A., Rovin B. H., Kunsch C., Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. American Journal of Physiology 2006 290 5 H1862 H1870 2-s2.0-33646418968 10.1152/ajpheart.00651.2005
85. Chen B., Ma Y., Meng R., Xiong Z., Zhang C., Chen G., Zhang A., Dong Y., MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochimica et Biophysica Sinica 2010 42 4 253 258 2-s2.0-77950553729 10.1093/abbs/gmq012
86. Wang Y., Sun W., Du B., Therapeutic effect of MG132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. American Journal of Physiology 2013 304 4 567 578
87. Miao X., Bai Y., Su W., Sulforaphane prevention of diabetes-induced aortic damage was associated with the up-regulation of Nrf2 and its down-stream antioxidants. Nutrition & Metabolism 2012 9 1 84
88. Chen J., Regan R. F., Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury. Current Neurovascular Research 2005 2 3 189 196 2-s2.0-22144481954 10.2174/1567202054368344 (Pubitemid 40980178)
89. Alonso de Vega J. M., Díaz J., Serrano E., Carbonell L. F., Oxidative stress in critically ill patients with systemic inflammatory response syndrome. Critical Care Medicine 2002 30 8 1782 1786 2-s2.0-0036345689 (Pubitemid 34879591)
90. Molitoris B. A., Marrs J., The role of cell adhesion molecules in ischemic acute renal failure. American Journal of Medicine 1999 106 5 583 592 2-s2.0-0033135667 10.1016/S0002-9343(99)00061-3 (Pubitemid 29231111)
91. Sun Q., Meng Q. T., Jiang Y., Xia Z. Y., Ginsenoside Rb1 attenuates intestinal ischemia reperfusion induced renal injury by activating Nrf2/ARE pathway. Molecules 2012 17 6 7195 7205
92. Couser W. G., Nangaku M., Cellular and molecular biology of membranous nephropathy. Journal of Nephrology 2006 19 6 699 705 2-s2.0-33947226955 (Pubitemid 46415972)
93. Neale T. J., Ojha P. P., Exner M., Poczewski H., Ruger B., Witztum J. L., Davis P., Kerjaschki D., Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. The Journal of Clinical Investigation 1994 94 4 1577 1584 2-s2.0-0028136960 (Pubitemid 24309880)
94. Rodríguez-Iturbe B., Vaziri N. D., Herrera-Acosta J., Johnson R. J., Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. American Journal of Physiology 2004 286 4 F606 F616 2-s2.0-1642368265 (Pubitemid 38365077)
95. Budisavljevic M. N., Hodge L., Barber K., Fulmer J. R., Durazo-Arvizu R. A., Self S. E., Kuhlmann M., Raymond J. R., Greene E. L., Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. American Journal of Physiology 2003 285 6 F1138 F1148 2-s2.0-0242581714 (Pubitemid 37421050)
96. Shah S. V., Oxidants and iron in chronic kidney disease. Kidney International, Supplement 2004 66 91 S50 S55 2-s2.0-4644225485 (Pubitemid 39281715)
97. Lee H. B., Yu M. R., Yang Y., Jiang Z., Ha H., Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. Journal of the American Society of Nephrology 2003 14 8, supplement 3 S241 S245 2-s2.0-0042867408 (Pubitemid 36903933)
98. Lal M. A., Brismar H., Eklöf A. C., Aperia A., Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney International 2002 61 6 2006 2014 2-s2.0-0036098848 10.1046/j.1523-1755. 2002.00367.x (Pubitemid 34539318)
99. Kang B. P., Frencher S., Reddy V., Kessler A., Malhotra A., Meggs L. G., High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. American Journal of Physiology 2003 284 3 455 466
100. Iglesias-De La Cruz M. C., Ruiz-Torres P., Alcamí J., Díez-Marqués L., Ortega-Velázquez R., Chen S., Rodríguez-Puyol M., Ziyadeh F. N., Rodríguez-Puyol D., Hydrogen peroxide increases extracellular matrix mRNA through TGF- β in human mesangial cells. Kidney International 2001 59 1 87 95 2-s2.0-0035171881 10.1046/j.1523-1755.2001.00469.x (Pubitemid 32055217)
101. Ozcelik D., Naziroglu M., Tuncdemir M., Celik O., Ozturk M., Flores-Arce M. F., Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats. Biological Trace Element Research 2012 150 1-3 342 349
102. Foster M. H., T cells and B cells in lupus nephritis. Seminars in Nephrology 2007 27 1 47 58 2-s2.0-33847277400 10.1016/j.semnephrol.2006.09.007
103. Yoh K., Itoh K., Enomoto A., Hirayama A., Yamaguchi N., Kobayashi M., Morito N., Koyama A., Yamamoto M., Takahashi S., Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney International 2001 60 4 1343 1353 2-s2.0-0034785941 10.1046/j.1523-1755.2001.00939.x (Pubitemid 32960028)
104. Moroni G., Novembrino C., Quaglini S., De Giuseppe R., Gallelli B., Uva V., Montanari V., Messa P., Bamonti F., Oxidative stress and homocysteine metabolism in patients with lupus nephritis. Lupus 2010 19 1 65 72 2-s2.0-74849130229 10.1177/0961203309346906
105. Falk R. J., Jennette J. C., ANCA are pathogenicoh-oh yes they are! Journal of the American Society of Nephrology 2002 13 7 1977 1979 2-s2.0-0035987347 (Pubitemid 34700626)
106. Harper L., Ren Y., Savill J., Adu D., Savage C. O. S., Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. American Journal of Pathology 2000 157 1 211 220 2-s2.0-0033872054 (Pubitemid 30641738)
107. Chade A. R., Herrmann J., Zhu X., Krier J. D., Lerman A., Lerman L. O., Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. Journal of the American Society of Nephrology 2005 16 4 1005 1012 2-s2.0-20044393709 10.1681/ASN.2004080674 (Pubitemid 41710311)
108. Chatterjee P. K., Yeboah M. M., Dowling O., Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. PLoS One 2012 7 5 e35361
109. Liu L., Yang C., Herzog C., Seth R., Kaushal G. P., Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochemical Pharmacology 2010 79 2 137 146 2-s2.0-71749119515 10.1016/j.bcp.2009.08.015
110. Sakairi T., Hiromura K., Takahashi S., Hamatani H., Takeuchi S., Tomioka M., Maeshima A., Kuroiwa T., Nojima Y., Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology 2011 16 1 76 86 2-s2.0-78650637670 10.1111/j.1440-1797.2010.01367.x
111. Wu H., Jiang W., Zhang Y., Liu Y., Zhao Z., Guo M., Ma D., Zhang Z., Regulation of intracellular decorin via proteasome degradation in rat mesangial cells. Journal of Cellular Biochemistry 2010 111 4 1010 1019 2-s2.0-78049238210 10.1002/jcb.22789
112. Cui W., Bai Y., Miao X., Prevention of diabetic nephropathy by sulforaphane: possible role of nrf2 upregulation and activation. Oxidative Medicine and Cellular Longevity 2012 2012 12 821936 10.1155/2012/821936
113. Cui W., Li B., Bai Y., Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. American Journal of Physiology 2013 304 1 87 99
114. Stangl K., Günther C., Frank T., Lorenz M., Meiners S., Röpke T., Stelter L., Moobed M., Baumann G., Kloetzel P. M., Stangl V., Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochemical and Biophysical Research Communications 2002 291 3 542 549 2-s2.0-18444410992 10.1006/bbrc.2002.6476 (Pubitemid 34687378)
115. Lüss H., Schmitz W., Neumann J., A proteasome inhibitor confers cardioprotection. Cardiovascular Research 2002 54 1 140 151 2-s2.0-0036217315 10.1016/S0008-6363(02)00232-8 (Pubitemid 34327944)
116. Drexler H. C. A., Risau W., Konerding M. A., Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB Journal 2000 14 1 65 77 2-s2.0-0033965742 (Pubitemid 30051524)
117. Han Y. H., Kim S. Z., Kim S. H., Park W. H., Treatment with p38 inhibitor intensifies the death of MG132-treated As4.1 juxtaglomerular cells via the enhancement of GSH depletion. Drug and Chemical Toxicology 2010 33 4 367 376 2-s2.0-77956158547 10.3109/01480540903483458
118. Han Y. H., Park W. H., The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death. Chemico-Biological Interactions 2010 184 3 319 327 2-s2.0-77949915298 10.1016/j.cbi.2010.01.033
119. Han Y. H., Park W. H., Proteasome inhibitor MG132 reduces growth of As4.1 juxtaglomerular cells via caspase-independent apoptosis. Archives of Toxicology 2010 84 9 689 698 2-s2.0-77957778815 10.1007/s00204-010-0550-8
120. Meiners S., Ludwig A., Lorenz M., Dreger H., Baumann G., Stangl V., Stangl K., Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radical Biology and Medicine 2006 40 12 2232 2241 2-s2.0-33745227748 10.1016/j.freeradbiomed.2006.03.003 (Pubitemid 43922398)
121. Liu H., Yu S., Xu W., Xu J., Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2131 2140
122. Gao X., Zhang H., Schmidt A. M., Zhang C., AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice. American Journal of Physiology 2008 295 2 H491 H498 2-s2.0-52449094718 10.1152/ajpheart.00464.2008
123. Kolev K., Skopál J., Simon L., Csonka É., Machovich R., Nagy Z., Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NF- B as a signal transducer. Thrombosis and Haemostasis 2003 90 3 528 537 2-s2.0-0141540646 (Pubitemid 37138779)
124. Ma Y., Chen Y., Yang Y., Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression. Biochemical Pharmacology 2013 85 2 223 233
125. Singh A. B., Guleria R. S., Nizamutdinova I. T., Baker K. M., Pan J., High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling. Journal of Cellular Physiology 2012 227 6 2632 2644
126. Wang S., Zhang M., Liang B., Xu J., Xie Z., Liu C., Viollet B., Yan D., Zou M. H., AMPK α 2 deletion causes aberrant expression and activation of NAD(P)H Oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circulation Research 2010 106 6 1117 1128 2-s2.0-77950989801 10.1161/CIRCRESAHA.109.212530
127. Xu J., Wang S., Zhang M., Wang Q., Asfa S., Zou M. H., Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors. PloS One 2012 7 1 e29649
128. Dinkova-Kostova A. T., Liby K. T., Stephenson K. K., Holtzclaw W. D., Gao X., Suh N., Williams C., Risingsong R., Honda T., Gribble G. W., Sporn M. B., Talalay P., Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America 2005 102 12 4584 4589 2-s2.0-20144383831 10.1073/pnas.0500815102 (Pubitemid 40397155)
129. Pergola P. E., Raskin P., Toto R. D., Meyer C. J., Huff J. W., Grossman E. B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D. G., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine 2011 365 4 327 336 2-s2.0-79960855656 10.1056/NEJMoa1105351
130. Moore B. S., Eustáquio A. S., McGlinchey R. P., Advances in and applications of proteasome inhibitors. Current Opinion in Chemical Biology 2008 12 4 434 440 2-s2.0-50449091498 10.1016/j.cbpa.2008.06.033
131. Chauhan D., Hideshima T., Anderson K. C., A novel proteasome inhibitor NPI-0052 as an anticancer therapy. British Journal of Cancer 2006 95 8 961 965 2-s2.0-33750209537 10.1038/sj.bjc.6603406 (Pubitemid 44606819)